Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,119,768
  • Shares Outstanding, K 1,306,270
  • Annual Sales, $ 30,390 M
  • Annual Income, $ 13,501 M
  • 36-Month Beta 1.13
  • Price/Sales 3.19
  • Price/Cash Flow 5.89
  • Price/Book 3.84

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.05 +6.78%
on 11/14/17
76.27 -1.93%
on 12/11/17
+1.03 (+1.40%)
since 11/10/17
3-Month
70.05 +6.78%
on 11/14/17
84.73 -11.72%
on 09/26/17
-9.71 (-11.49%)
since 09/12/17
52-Week
63.76 +17.31%
on 06/16/17
86.27 -13.30%
on 09/08/17
+1.33 (+1.81%)
since 12/12/16

Most Recent Stories

More News
Bluebird's Shares Jump on Strong Data for CAR-T Therapy

bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.

CELG : 109.37 (+1.27%)
BLUE : 198.85 (-1.46%)
GILD : 74.91 (-1.28%)
JUNO : 48.26 (-3.94%)
Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

-- Results Presented at the Annual Meeting of the American Society of Hematology --

GILD : 74.91 (-1.28%)
Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta

Gilead (GILD) announced follow-up data from a phase II study, on its CAR-T therapy, Yescarta for treatment of refractory large B-cell lymphoma.

CELG : 109.37 (+1.27%)
NVS : 84.05 (+0.30%)
GILD : 74.91 (-1.28%)
JUNO : 48.26 (-3.94%)
Novartis Reports Updated Results from Kymriah's JULIET Study

Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.

CELG : 109.37 (+1.27%)
BLUE : 198.85 (-1.46%)
NVS : 84.05 (+0.30%)
GILD : 74.91 (-1.28%)
Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today

Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients...

CELG : 109.37 (+1.27%)
BLUE : 198.85 (-1.46%)
NVS : 84.05 (+0.30%)
GILD : 74.91 (-1.28%)
Company News For Dec 11, 2017

Companies in the news are: GILD,AOBC,UNFI,UAL

UAL : 64.12 (-0.19%)
AOBC : 14.44 (+4.71%)
UNFI : 49.68 (+0.12%)
GILD : 74.91 (-1.28%)
3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise

With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.

BLUE : 198.85 (-1.46%)
JNJ : 142.92 (+1.26%)
INCY : 96.33 (-0.95%)
GILD : 74.91 (-1.28%)
AMGN : 174.45 (-1.35%)
JUNO : 48.26 (-3.94%)
SNY : 43.92 (+0.50%)
Thinking about investing in bluebird bio Inc., Celgene, Gilead Sciences, SunPower or Waste Management?

InvestorsObserver issues critical PriceWatch Alerts for BLUE, CELG, GILD, SPWR, and WM.

CELG : 109.37 (+1.27%)
BLUE : 198.85 (-1.46%)
WM : 84.84 (-0.62%)
GILD : 74.91 (-1.28%)
CELGZ : 1.05 (unch)
SPWR : 8.83 (-4.33%)
Today's Research Reports on Stocks to Watch: Gilead Sciences and Alexion Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / December 11, 2017 / Shares of Gilead Sciences crept higher on Friday by a little over 2%. The company had exciting news this weekend revealing that the company's Yescarta therapy,...

GILD : 74.91 (-1.28%)
ALXN : 114.07 (+1.94%)
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta(TM) (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma

-- Data Presented at the Annual Meeting of the American Society of Hematology and Published in The New England Journal of Medicine --

GILD : 74.91 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. They strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and...

See More

Key Turning Points

2nd Resistance Point 77.39
1st Resistance Point 76.64
Last Price 74.87
1st Support Level 74.76
2nd Support Level 73.63

See More

52-Week High 86.27
Fibonacci 61.8% 77.67
Fibonacci 50% 75.01
Last Price 74.87
Fibonacci 38.2% 72.36
52-Week Low 63.76

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.